In addition, HCC patients with high ATP7A expression have higher sensitivity to sorafenib, suggesting that ATP7A may serve as a biomarker to predict response to sorafenib treatment in HCC patients (Shao et al., 2023). Here, ATP7A is linked to hepatocellular carcinoma.